Immix Biopharma Inc (IMMX)
2.00
-0.13
(-6.10%)
USD |
NASDAQ |
Jun 28, 16:00
2.00
0.00 (0.00%)
After-Hours: 17:08
Immix Biopharma Total Liabilities (Quarterly): 6.716M for March 31, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 6.716M |
| December 31, 2023 | 3.722M |
| September 30, 2023 | 2.826M |
| June 30, 2023 | 2.396M |
| March 31, 2023 | 1.473M |
| December 31, 2022 | 1.748M |
| September 30, 2022 | 0.6465M |
| Date | Value |
|---|---|
| June 30, 2022 | 0.9772M |
| March 31, 2022 | 0.3651M |
| December 31, 2021 | 0.202M |
| September 30, 2021 | 6.691M |
| June 30, 2021 | 6.202M |
| December 31, 2020 | 5.270M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
0.202M
Minimum
Dec 2021
6.716M
Maximum
Mar 2024
3.018M
Average
2.396M
Median
Jun 2023
Total Liabilities (Quarterly) Benchmarks
| RenovoRx Inc | 3.021M |
| CEL-SCI Corp | 15.74M |
| AIM ImmunoTech Inc | 11.36M |
| IGC Pharma Inc | 2.581M |
| NovaBay Pharmaceuticals Inc | 5.197M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 34.35M |
| Shareholders Equity (Quarterly) | 27.92M |